RNA technology Archives

dystrophic epidermolysis bullosa proqr rna therapy

News and Trends 30 Nov 2017

RNA Therapy for Rare Skin Disease Gets Orphan Status

The EMA has granted orphan drug designation to ProQR’s QR-313, a possible first disease-modifying treatment for the rare disease dystrophic epidermolysis bullosa. Dystrophic epidermolysis bullosa (DEB) is a genetic disease that causes the skin to easily blister, severely affecting the quality of life of patients since a very early age. Current treatment is limited to […]

November 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Infographics 22 Nov 2017

Infographic: What is RNAi Therapy? Targeting the Untargetable

Everything you need to know about what RNAi is, how it works and how it could soon change the way we treat all sorts of diseases. A new wave of therapies based on RNA interference is on the brink of making it to the market. A technology that was awarded the Nobel prize in 2006, […]

November 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2017

Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low

ProQR is aiming to raise funds for clinical trials on the Nasdaq despite the fact that its stock has been down for a while now. ProQR is a biotech based in Leiden that develops RNA therapies for genetic disorders, with its lead program focused on cystic fibrosis. In order to fund clinical trials, research and […]

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Nov 2017

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […]

November 8, 2017 - 3 minutesmins - By Alex Dale

More News! 14 Sep 2017

New Dutch Spin Out will Treat Stroke with RNA Therapy

ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […]

September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2017

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make the immune system attack cancer cells. After selling selling Sirna Therapeutics three years ago for almost a tenth of the acquisition price, it seemed like MSD was out of the RNA field. However, the big […]

September 6, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the start of a Phase III program that seeks to recruit 250 patients to test its RNAi drug fitusiran in patients with both hemophilia A and […]

July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 May 2017

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […]

May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Jan 2017

RNA Spray fights Viruses and could Sidestep problems with GMOs

RNA and clay could be the future of crop protection and manipulation of plants’ traits. Researchers have managed to use these ingredients to create a spray capable of “vaccinating” plants, teaching them to recognize the genetic material of viruses. RNA-based therapies may have suffered a recent blow in the clinic this week, but when it comes […]

January 13, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 5 Jan 2017

Shire sells its RNA platform to a US-based Biotech

Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […]

January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

CRISPR meets RNAi: a whole new Targeted Therapy

Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

RNA technology

RNA Therapy for Rare Skin Disease Gets Orphan Status

Infographic: What is RNAi Therapy? Targeting the Untargetable

Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

New Dutch Spin Out will Treat Stroke with RNA Therapy

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

RNA Spray fights Viruses and could Sidestep problems with GMOs

Shire sells its RNA platform to a US-based Biotech

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

CRISPR meets RNAi: a whole new Targeted Therapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!